T he kidneys are exposed to an extraordinary volume of blood flow under a wide range of hemodynamic conditions. The relatively low vascular resistance that enables such a high flow rate also renders the kidneys vulnerable to barotrauma because they are susceptible to the pulsatile aspects of blood pressure (BP) and blood flow. In particular, excessive pulsatility in BP damages the glomerulus resulting in proteinuria and a loss of kidney function. 1 The low resistance in the kidney allows the pressure wave of each heartbeat to penetrate deeply into the microvasculature in animal models. 2 Prospective studies in humans show that elevated BP plays a substantial role in initiating kidney damage and participates in the progressive loss of kidney function that frequently ensues once kidney function impairment is detected. 3, 4 the vasodilated state of the kidney suggests it would be an important influence. 2 Some studies of patients with CKD support an independent role for arterial stiffness in kidney function decline in established CKD, 10, 11 whereas others do not. [12] [13] [14] To examine the role of arterial stiffness in CKD patients with impaired kidney function but not on dialysis, we evaluated the relationship between aortic PWV as an independent predictor of CKD progression and death from any cause, among men and women enrolled in the CRIC study (Chronic Renal Insufficiency Cohort).
Methods
The demographic data on this CRIC cohort are available at the National Institute of Diabetes and Digestive and Kidney Diseases website repository by request (https://repository.niddk.nih.gov/studies/cric/?query=None accessed February 13 2018) . The PWV data were not publicly available at the time of this article's submission. This is an ancillary study to the CRIC study. The CRIC study enrolled 3939 men and women with CKD between May 2003 and August 2008 at 7 US clinical centers (Ann Arbor, MI; Baltimore, MD; Chicago, IL; Cleveland, OH; New Orleans, LA; Oakland, CA; and Philadelphia, PA). They were aged 21 to 74 years with an estimated glomerular filtration rate (eGFR) of 20 to 70 mL/min per 1.73 m 2 . The design of the study and the baseline characteristics of the participants were described previously. 15, 16 People with prior dialysis for >1 month, New York Heart Association class III/IV heart failure, polycystic kidney disease, or other primary renal diseases requiring active immunosuppression, HIV infection, and pregnancy were not enrolled. Each year, participants underwent an in-person study visit and an interim (6 months) telephone contact. Measurements of PWV were begun in July 2005. Most participants (72%) had their first PWV measurement on, or before, the second year in-center follow-up visit. The study was approved by the institutional review board of each site, and written informed consent was obtained from all study participants.
Brachial BP Measurement
At the annual clinic visit, 3 seated BP measurements were obtained using a Tyco Classic aneroid sphygmomanometer following a standardized protocol. 17 The average seated brachial BP measurement was used as the BP value. Brachial mean arterial pressure (MAP) was calculated as the diastolic BP plus one third of the (systolic−diastolic) BP. Brachial pulse pressure was calculated by subtracting the diastolic BP from the systolic BP value.
PWV Measurement
Methods for assessment of aortic PWV in the CRIC study have been described previously. 18 Briefly, carotid-to-femoral PWV measurements were performed in the supine position after at least 5 minutes of rest. Three electrocardiographic leads were attached: 1 to the right arm, 1 to the left arm, and 1 to the left lower abdomen or leg providing a standard limb lead II electrocardiographic tracing. The head was turned between 45 and 60° away from the examiner, and the right carotid pulse was palpated. The distance from the suprasternal notch to the point of the palpable carotid pulse was measured in millimeters. The right femoral pulse was palpated, and the distance to the umbilicus from the suprasternal notch and then from the umbilicus to the point of femoral palpation was also measured. The travel distance was the notch-to-femoral distance minus the notch-to-carotid distance. A Millar tonometer attached to an electronic module interface was placed perpendicular to the carotid pulse and repositioned in small increments until a stable wave form was observed. 9 Pulse waveforms from right carotid and right femoral arteries were captured with the Sphygmocor PVx System (AtCor Medical, Sydney, Australia). 18 The operator captured 10 seconds of stable carotid waveform and repeated the sequence using the femoral artery. After second waveform capture, the computer generated a PWV value with an SD. If the SD was >15% of the PWV value, the study was repeated. Because of the large waist size in many CRIC participants, which artificially increases the sternal notch to umbilicus distance, we applied a correction to this distance using a formula incorporating waist size, sex, and height. 18 
Outcomes
At each yearly visit, and each 6-month intermittent phone contact, participants were queried on interval medical history, including hospitalizations. Serum creatinine and cystatin C were measured yearly to estimate glomerular filtration rates. 16, 19 Outcomes were ESRD, a 50% reduction in eGFR and ESRD, or death from any cause occurring after the first PWV measurement. ESRD, defined as receiving dialysis or a kidney transplant, was determined by participant self-report/local clinical center ascertainment and supplemented by cross-linkage with the United States Renal Data System. Deaths from all causes were determined through contact with surviving family members and adjudicated by 2 CRIC study physicians, supplemented by cross-linkage to the Social Security Death Master File. 15 Participant follow-up in this study was censored either at the time of death, withdrawal, lost to follow-up, or the end of the follow-up period (March 2013).
Data and Analyses
Data are expressed as mean±SD or proportions (percentage) where appropriate. For unadjusted tests of differences between groups, ANOVA was used for continuous variables, and χ 2 tests were used for categorical variables.
To compare whether subjects who had successful PWV measurement differed from those who did not, we stratified on whether PWV was obtained and compared summary statistics on a wide range of variables. We used the baseline period for entry into the CRIC study to compare demographic and clinical characteristics of people who did with those who did not have PWV measured. This was because the time of PWV measurement occurred at different points in follow-up.
For time-to-event analyses, the index visit or time 0 was the visit at which each subject first had a PWV measurement. Covariate information that was obtained at or before that visit was used in multivariable analyses. Cox proportional hazards models were for the 3 time-toevent outcomes. We used splines to test for departures from linearity in our predictors of interest: MAP and PWV. If there was evidence of nonlinearity, then tertiles would be used. The reason for using tertiles rather than some other model that does categorize the exposures (such as splines) is that nonlinear relationships are more difficult to interpret, and we do not expect any loss of power to be a major concern from a study of this size.
For each outcome, MAP and PWV were included in the Cox model, along with established risk factors: age, sex, race, proteinuria, eGFR, and study site. Because the relationship between PWV and the outcomes might vary with MAP, we also fitted models that included interactions between PWV and MAP. We formally tested for significance of both the main effects and interactions.
Kaplan-Meier curves, stratified by tertiles of PWV, were used to graphically summarize the (unadjusted) relationship between PWV and the time-to-event outcomes. Sensitivity analyses were performed using multiple imputation for any missing covariates, which increased the sample size because of the distribution of missing data but did not meaningfully influence the results.
Results
Among the 3939 enrolled CRIC participants, 2795 had a successful carotid-femoral PWV measurement, typically in their second year of follow-up. Figure 1 shows the participant flow in this study. Table 1 presents the baseline characteristics of the CRIC participants in whom carotid-femoral PWV was compared with those in whom it was not successfully obtained. As we reported previously, those in whom a carotid-femoral PWV could not be obtained had higher body mass index, lower eGFR, and lower hemoglobin levels. 18 The mean age of our cohort was 60 years, 56.4% were men, 47.3% had diabetes mellitus, and the average eGFR at entry into this ancillary study was 44.4 mL/min per 1.73 m 2 . The mean follow-up time for the ESRD outcome was 4.9±2.1 years. The mean follow-up time for the ESRD or halving of eGFR was 4.1±2.3 years. The mean follow-up time (+SD) for the outcome of death was 5.4±1.8 years. During follow-up, there were 504 ESRD events, 628 ESRD or halving of eGFR events, and 394 deaths.
The analysis of PWV as a continuous variable in the Cox proportional hazards survival analyses demonstrated a nonlinear relationship of PWV to ESRD, halving of eGFR/ESRD, and death outcomes; thus, tertiles of PWV were used instead as we published previously.
8 Table 2 shows the complete multivariable regression model components for the 3 outcomes Figure 2 depicts the adjusted hazards of each outcome with the lowest tertile of PWV as the referent group showing the independent relationship of PWV in the highest tertile for each outcome. Our basic model in Table 2 was enlarged further to include body mass index, triglyceride concentrations, heart rate, smoking, and usage of angiotensin converting enzyme inhibitor or angiotensin receptor blocker therapy (Table S1 in the online-only Data Supplement). The addition of these covariates did not alter the statistical significance of hazard ratios associated with the highest PWV tertile on the 3 outcomes. Figure 3 shows a Kaplan-Meier plot of the unadjusted relationship of PWV tertiles to the 3 outcomes. In Table  S2 , an analysis of the 3 outcomes stratified by eGFR <30 versus >30 mL/min per 1.73 m 2 showed that the hazard for death was higher in the subgroup with more preserved kidney function and that the hazard for the kidney outcomes was higher in those with the lower values of kidney function.
Discussion
Among people with primarily stages 3 and 4 CKD, including substantial proportions of blacks and people with diabetes mellitus, we observed that aortic PWV independently predicted both measures of CKD progression, and all-cause death, when evaluated in models that adjusted for MAP. In all these analyses, the models incorporated important covariates that predict death or kidney function loss, including BP, eGFR, proteinuria, diabetes mellitus, age, sex, and race. These observations add to our initial investigations of the importance of aortic PWV in CKD 18, 21 and are consistent with some prior investigations 10, 11 but not others. 13, 14 The positive and independent effects of arterial stiffness on death and worsening of kidney function we observed in our study are likely related to the large size of our cohort, the reasonably long follow-up of our participants, and the high degree of retention of our cohort.
PWV studies primarily focus on the velocity of pulse wave travel in the aorta because abundant literature attests to the value of studying this particular vascular bed. 7, 22 The recent scientific statement from the American Heart Association recommends using the aorta as the primary vessel in pursuing research into the relationship between arterial stiffness and outcomes. 20 Pursuing the role of arterial stiffness in CKD progression and outcomes, such as death, is complicated by effects of BP itself on PWV and vice versa. When using the carotid-femoral PWV as a factor involved in outcome, or when PWV is the target of an intervention, it should be adjusted by the MAP at the time it is measured, as recommended by the recent AHA statement.
BP influences the course of kidney disease progression, and prior work from the CRIC study confirms the importance of BP measurements in CKD progression. 4 Our data incorporating PWV into models predicting kidney disease progression are consistent with the observation of the vulnerability of the kidney to hemodynamic trauma given the remarkable vasodilation of the kidney, the torrential blood flow in the kidneys, and the penetration of the pulse wave deep into the microvasculature of the kidney. 2 Our findings are consistent with some studies of CKD progression, where arterial stiffness provides independent predictive potential, 10, 11 and are at odds with other studies, which did not find an independent association of arterial stiffness with CKD progression. 13, 14 In particular, the study by Michener et al did not find a relationship between PWV and eGFR in an older population; however, they felt that elderly age may have overshadowed any relationship. The large size of the CRIC study, the range of ages, ethnic diversity among the participants, the large proportion of diabetics, and the long follow-up in CRIC make it difficult to render comparisons with other CKD cohorts, which tend to be smaller and more ethnically homogenous.
The aortic PWV has shown an independent relationship to cardiovascular outcomes, including death, when factored into models that also include BP in longitudinal studies, including ESRD cohorts. 7 Although the PWV in an individual is influenced by the MAP, 23 other factors beside BP also contribute to arterial stiffness. 18 Moreover, antihypertensive treatment does not always improve arterial stiffness, despite effective reduction in BP. 5 Thus, measurements of PWV add complementary value to standard BP values and common demographic factors in predicting outcomes.
Aortic stiffening has a strong influence on left ventricular hypertrophy and coronary ischemia, which may explain the increase in cardiovascular mortality noted in longitudinal studies. [24] [25] [26] [27] [28] In studies incorporating aortic PWV prospectively, up to half of the deaths occur from noncardiovascular causes. 7 Although mechanisms linking measures of arterial stiffness to all-cause death remain to be determined, it is probable that common pathogenic processes, such as inflammation, aging, and oxidant stress, contribute both to arterial stiffness and to death from noncardiovascular causes. 7 Guidelines encourage performance of arterial stiffness measurements, arguing that PWV represents a valid intermediate surrogate for prediction of all-cause mortality. 29 Our observation in CRIC that PWV was a significant predictor of death is consistent with similar findings in ESRD. 24 A small study in Germany also observed an association of PWV with death in CKD stages 2 to 4. 6 Arterial stiffness is a contributing factor, independent of BP to incident CKD. In the Rotterdam Study, each 1 SD in PWV was associated with a 13% increase in the likelihood of incident CKD and with greater rate of progression of kidney function loss. 30 Similarly, a Japanese workplace study also observed a 36% higher likelihood of incident CKD with each 1-m/s increase in arterial stiffness. 
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